Follicle-Stimulating Hormone

Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced by the anterior pituitary gland, primarily involved in regulating reproductive processes in both males and females. Researchers primarily study FSH for its critical role in follicle development, ovulation, and its influence on reproductive health. Key findings indicate that FSH not only regulates granulosa cell function to control ovulation but also plays a role in glucose-stimulated insulin secretion in pancreatic islets, suggesting its broader physiological implications. Additionally, emerging studies highlight FSH's involvement in various extragonadal tissues, linking it to conditions such as bone loss and obesity, as well as potential roles in cancer biology. Current research continues to explore these diverse functions of FSH, emphasizing its significance in both reproductive and metabolic health.

Follicle-stimulating hormone (FSH) is an endogenous glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in the regulation of reproductive processes in both males and females. Chemically, FSH is a heterodimer composed of an alpha and a beta subunit, with the beta subunit conferring its specific biological activity. In addition to its natural form, synthetic versions such as Gonal-F and Follistim are used clinically. FSH is primarily involved in the regulation of the reproductive system, including the development of ovarian follicles in females and spermatogenesis in males. Researchers have found that FSH also influences extragonadal tissues, impacting metabolic processes such as glucose-stimulated insulin secretion and potentially contributing to conditions like polycystic ovary syndrome (PCOS) and postmenopausal diabetes. The mechanism of action of FSH involves binding to the follicle-stimulating hormone receptor (FSHR), which activates intracellular signaling pathways such as the cAMP/protein kinase A (PKA) and calcium pathways. This leads to various physiological effects, including the regulation of granulosa cell function and insulin secretion. Pharmacokinetic properties of FSH, particularly its synthetic forms, vary based on the route of administration, but detailed data on half-life and metabolism are limited. Clinically, FSH is used in assisted reproductive technologies and is regulated as a prescription medication in many countries. Researchers have observed its potential implications in cancer biology, though further studies are needed to fully understand its role and therapeutic potential in oncology.

FSH acts on the follicle-stimulating hormone receptor (FSHR), primarily activating the Gαs protein, which stimulates the cAMP/protein kinase A (PKA) and calcium pathways. This cascade promotes processes such as granulosa cell function and glucose-stimulated insulin secretion.

Follicle-stimulating hormone (FSH) exerts its effects primarily through binding to the follicle-stimulating hormone receptor (FSHR), activating the Gαs protein, which subsequently stimulates the cAMP/protein kinase A (PKA) pathway and calcium signaling. This signaling cascade promotes granulosa cell glutamine synthesis, inhibiting apoptosis via the ASK1-JNK apoptotic pathway, and orchestrates glucose-stimulated insulin secretion in pancreatic β-cells. While FSH's role in reproductive physiology is well-established, its mechanisms in extragonadal tissues and other biological processes remain incompletely understood.

Current evidence is limited regarding the precise mechanisms by which FSH influences extragonadal tissues, particularly in relation to metabolic disorders and cancer. Further research is needed to clarify the context-dependent effects of FSH signaling in various tumor types, necessitating larger randomized controlled trials (RCTs) that include diverse populations to assess the implications of FSHR-targeted therapies. Additionally, long-term studies are required to understand the endocrine consequences of manipulating myostatin and FSH levels on fertility and metabolic health.